The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The FDA grants tazemetostat (EPZ-6438) Fast Track Designation for treatment of DLBCL
Tazemetostat (EPZ-6438) is an orally administered, first-in-class, small molecule EZH2 inhibitor, which has recently been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with R/R DLBCL with EZH2-activating mutations.1
EZH2 is a Histone Methyltransferase (HMTs) and is mutated or overexpressed in a diverse range of cancer cells, and is a key player in cell proliferation. Tazemetostat selectively binds and inhibits wild type and mutated EZH2, and the resulting decrease in methylation alters gene expression patterns in cancer pathways leading to decreased proliferation in cancer cells harboring EZH2 mutations.2
The first-in-human, dose-escalation trial (NCT01897571) of tazemetostat as a single-agent in advanced solid tumors and B-cell lymphomas determined the Recommended Phase 2 Dose (RP2D) to be 800mg orally twice daily (BID).3 The phase II portion of this trial is now underway, which aims to investigate the safety and efficacy of tazemetostat in five independent cohorts as defined by histology, Cell of Origin (CoO), and EZH2 mutation status. The phase II portion is restricted to subjects with R/R DLBCL, including Primary Mediastinal B-Cell Lymphoma (PMBL), who are unfit/ineligible for ASCT, and R/R FL patients with no curative option with other available therapies.
Tazemetostat is also being evaluated in combination with 8 cycles of R-CHOP 21 in patients with previously untreated DLBCL, including de novo and transformed indolent disease. The estimated primary completion date is this summer (June 2017; NCT02889523).
Epizyme is also collaborating with Genentech to carry out a phase Ib clinical trial, which will evaluate combining tazemetostat with TecentriqTM (atezolizumab) is patients with R/R DLBCL.4
References